Precision BioSciences has regained control of three gene editing programs from Prevail Therapeutics, a subsidiary of Eli Lilly. The programs utilize Precision’s ARCUS platform for gene editing applications, including excision and insertion. The collaboration between Precision and Prevail resulted in significant advancements for three programs, including proof-of-concept data for gene excision and insertion.

Precision intends to independently develop or partner with others to advance these programs, capitalizing on the unique capabilities of the ARCUS platform. Precision highlighted promising proof-of-concept data for gene excision in the DMD program, targeting a specific “hot spot” region of the dystrophin gene. Additionally, gene insertion data in non-human primates showed up to 45% insertion efficiency in non-dividing cells, a key advantage over other editing technologies.

Regaining control of these programs does not affect Precision’s near-term clinical priorities in OTC deficiency, HBV, and PMM. The company’s cash runway remains sufficient to achieve these clinical milestones. Precision’s decision to focus on developing these programs independently or with partners reflects its commitment to delivering gene editing therapies for genetic diseases.

Source link: http://www.businesswire.com/news/home/20240416117356/en/Precision-BioSciences-Announces-Return-of-Programs-and-Conclusion-of-Collaboration-with-Prevail-Therapeutics

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.